Interim miss slows IO Biotech
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
Immutep tries again
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Bicara chases Merus
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
ASCO 2024 preview – with more patients Merus claims better efficacy
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
ASCO 2024 preview – Merus’s home run remains unconfirmed
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
